Geron (GERN) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

GERN Stock Forecast

Geron stock forecast is as follows: an average price target of $6.83 (represents a 90.52% upside from GERN’s last price of $3.58) and a rating consensus of 'Buy', based on 7 wall street analysts offering a 1-year stock forecast.

GERN Price Target

The average price target for Geron (GERN) is $6.83 based on 1-year price targets from 7 Wall Street analysts in the past 3 months, with a price target range of $8.00 to $5.50. This represents a potential 90.52% upside from GERN's last price of $3.58.

GERN Analyst Ratings

Buy

According to 7 Wall Street analysts, Geron's rating consensus is 'Buy'. The analyst rating breakdown for GERN stock is 0 'Strong Buy' (0.00%), 6 'Buy' (85.71%), 1 'Hold' (14.29%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Geron Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Nov 05, 2024	Emily Bodnar	H.C. Wainwright	$8.00	$4.24	88.68%	123.15%
Oct 22, 2024	Kalpit Patel	B.Riley Financial	$5.50	$3.95	39.24%	53.42%
Sep 09, 2024	Faisal Khurshid	Leerink Partners	$7.00	$4.25	64.71%	95.26%
Jun 10, 2024	Corinne Jenkins	Goldman Sachs	$6.00	$4.95	21.33%	67.36%
Jun 10, 2024	Stephen Willey	Stifel Nicolaus	$7.00	$4.59	52.51%	95.26%
Apr 30, 2024	Joel Beatty	Robert W. Baird	$4.50	$4.14	8.70%	25.52%
Mar 15, 2024	Gil Blum	Needham	$5.00	$3.36	48.81%	39.47%
Mar 15, 2024	Corinne Jenkins	Goldman Sachs	$5.00	$3.36	48.81%	39.47%
Jan 09, 2023		Needham	$4.00	$2.79	43.63%	11.58%
Jan 04, 2023		Wedbush	$6.00	$3.15	90.48%	67.36%

The latest Geron stock forecast, released on Nov 05, 2024 by Emily Bodnar from H.C. Wainwright, set a price target of $8.00, which represents a 88.68% increase from the stock price at the time of the forecast ($4.24), and a 123.15% increase from GERN last price ($3.58).

Geron Price Target by Period

	1M	3M	12M
# Anlaysts	-	2	8
Avg Price Target	-	$6.75	$6.00
Last Closing Price	$3.58	$3.58	$3.58
Upside/Downside	-100.00%	88.28%	67.36%

In the current month, the average price target of Geron stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Geron's last price of $3.58. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Nov 05, 2024	H.C. Wainwright		Buy	Initialise
Oct 03, 2024	Goldman Sachs	Buy	Buy	Hold
Aug 09, 2024	B. Riley	Buy	Buy	Hold
Jun 10, 2024	Goldman Sachs	Buy	Buy	Hold
Jun 10, 2024	Wedbush	Buy	Buy	Hold
Jun 10, 2024	Barclays		Overweight	Initialise
Jun 07, 2024	Cowen & Co.	Buy	Buy	Hold
Apr 29, 2024	Wedbush	Buy	Buy	Hold
Apr 29, 2024	Needham	Underperform	Underperform	Hold
Sep 12, 2023	Goldman Sachs	Neutral	Buy	Upgrade
Sep 12, 2023	Seaport Global		Neutral	Initialise
Jan 09, 2023	Needham	Buy	Buy	Hold
Jan 04, 2023	Wedbush	Outperform	Outperform	Hold

Geron's last stock rating was published by H.C. Wainwright on Nov 05, 2024. The company Initialise its GERN rating from "null" to "Buy".

Geron Financial Forecast

Geron Revenue Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Jun 18	Mar 17
Revenue	-	-	-	-	-	-	-	-	-	$164.00K	$29.00K	$21.00K	$103.00K	$297.00K	$73.00K	$123.00K	$1.04M	$109.00K	$107.00K	$137.00K	$50.00K	$108.00K	$43.00K	$52.00K	$171.00K	$131.00K	$101.00K	$57.00K	$208.00K	$537.00K
Avg Forecast	$95.40M	$81.82M	$69.13M	$57.06M	$61.93M	$18.97M	$344.80K	$28.83K	$81.50K	$59.00K	$66.00K	$70.00K	$124.50K	$87.17K	$114.60K	$102.25K	$77.25K	$101.75K	$83.33K	$62.50K	$70.00K	$77.00K	$55.60K	$53.50K	$73.20K	$50.00K	$100.33K	$142.67K	$210.00K	$540.00K
High Forecast	$168.48M	$144.50M	$122.08M	$70.40M	$138.04M	$19.37M	$344.90K	$28.92K	$87.32K	$104.19K	$116.56K	$123.62K	$219.87K	$87.17K	$114.60K	$102.25K	$77.25K	$101.75K	$83.33K	$62.50K	$70.00K	$77.00K	$55.60K	$53.50K	$73.20K	$50.00K	$100.33K	$142.67K	$252.00K	$648.00K
Low Forecast	$68.48M	$58.73M	$49.62M	$45.85M	$37.32M	$18.58M	$344.70K	$28.75K	$75.68K	$42.35K	$47.37K	$50.24K	$89.36K	$87.17K	$114.60K	$102.25K	$77.25K	$101.75K	$83.33K	$62.50K	$70.00K	$77.00K	$55.60K	$53.50K	$73.20K	$50.00K	$100.33K	$142.67K	$168.00K	$432.00K
# Analysts	1	1	1	4	6	3	1	1	3	1	1	1	1	1	1	1	1	1	1	7	5	5	9	6	4	4	7	4	11	7
Surprise %	-	-	-	-	-	-	-	-	-	2.78%	0.44%	0.30%	0.83%	3.41%	0.64%	1.20%	13.46%	1.07%	1.28%	2.19%	0.71%	1.40%	0.77%	0.97%	2.34%	2.62%	1.01%	0.40%	0.99%	0.99%

Geron's average Quarter revenue forecast for Dec 23 based on 3 analysts is $81.50K, with a low forecast of $75.68K, and a high forecast of $87.32K. GERN's average Quarter revenue forecast represents a -50.30% decrease compared to the company's last Quarter revenue of $164.00K (Sep 23).

Geron EBITDA Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Jun 18	Mar 17
# Analysts	1	1	1	4	6	3	1	1	3	1	1	1	1	1	1	1	1	1	1	7	5	5	9	6	4	4	7	4	11	7
EBITDA	-	-	-	-	-	-	-	-	-	$-47.61M	$-51.95M	$-36.20M	$-40.63M	$-39.23M	$-26.32M	$-28.42M	$-30.66M	$-25.45M	$-28.58M	$-26.90M	$-22.87M	$-19.51M	$-15.46M	$-16.08M	$-28.33M	$-15.17M	$-14.23M	$-10.04M	$-6.92M	$-7.14M
Avg Forecast	$-95.40M	$-81.82M	$-69.13M	$-57.06M	$-61.93M	$-18.97M	$-344.80K	$-43.50M	$-81.50K	$-59.00K	$-66.00K	$-39.55M	$-7.88M	$-87.17K	$-114.60K	$-31.26M	$-77.25K	$-101.75K	$-83.33K	$-23.54M	$-70.00K	$-77.00K	$-55.60K	$-21.45M	$-73.20K	$-50.00K	$-100.33K	$-12.91M	$-6.92M	$-7.14M
High Forecast	$-68.48M	$-58.73M	$-49.62M	$-45.85M	$-37.32M	$-18.58M	$-344.70K	$-34.80M	$-75.68K	$-42.35K	$-47.37K	$-31.64M	$-6.31M	$-87.17K	$-114.60K	$-25.01M	$-77.25K	$-101.75K	$-83.33K	$-18.83M	$-70.00K	$-77.00K	$-55.60K	$-17.16M	$-73.20K	$-50.00K	$-100.33K	$-10.33M	$-5.54M	$-5.71M
Low Forecast	$-168.48M	$-144.50M	$-122.08M	$-70.40M	$-138.04M	$-19.37M	$-344.90K	$-52.20M	$-87.32K	$-104.19K	$-116.56K	$-47.46M	$-9.46M	$-87.17K	$-114.60K	$-37.52M	$-77.25K	$-101.75K	$-83.33K	$-28.25M	$-70.00K	$-77.00K	$-55.60K	$-25.73M	$-73.20K	$-50.00K	$-100.33K	$-15.50M	$-8.30M	$-8.57M
Surprise %	-	-	-	-	-	-	-	-	-	806.98%	787.14%	0.92%	5.15%	450.10%	229.67%	0.91%	396.84%	250.11%	343.00%	1.14%	326.76%	253.42%	277.97%	0.75%	387.01%	303.42%	141.81%	0.78%	1.00%	1.00%

undefined analysts predict GERN's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Geron's previous annual EBITDA (undefined) of $NaN.

Geron Net Income Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Jun 18	Mar 17
# Analysts	1	1	1	4	6	3	1	1	3	1	1	1	1	1	1	1	1	1	1	7	5	5	9	6	4	4	7	4	11	7
Net Income	-	-	-	-	-	-	-	-	-	$-44.80M	$-49.23M	$-38.07M	$-42.41M	$-40.83M	$-28.26M	$-31.52M	$-33.15M	$-26.70M	$-29.57M	$-27.82M	$-23.79M	$-19.65M	$-15.82M	$-16.36M	$-29.07M	$-15.18M	$-14.24M	$-10.06M	$-6.93M	$-7.18M
Avg Forecast	$-5.99M	$-11.80M	$-19.49M	$-25.54M	$-20.76M	$-55.57M	$-68.21M	$-46.07M	$-53.30M	$-64.01M	$-55.18M	$-41.88M	$-7.92M	$-61.03M	$-61.47M	$-33.11M	$-54.93M	$-57.54M	$-56.24M	$-24.35M	$-42.50M	$-37.05M	$-40.54M	$-21.81M	$-133.40M	$-101.36M	$-58.85M	$-12.93M	$-6.93M	$-7.18M
High Forecast	$-3.79M	$-7.47M	$-12.34M	$-8.51M	$124.58M	$-35.18M	$-43.19M	$-36.86M	$-44.02M	$-40.53M	$-34.94M	$-33.51M	$-6.33M	$-61.03M	$-61.47M	$-26.49M	$-54.93M	$-57.54M	$-56.24M	$-19.48M	$-42.50M	$-37.05M	$-40.54M	$-17.45M	$-133.40M	$-101.36M	$-58.85M	$-10.35M	$-5.55M	$-5.75M
Low Forecast	$-11.96M	$-23.55M	$-38.90M	$-42.56M	$-124.58M	$-110.90M	$-136.13M	$-55.28M	$-62.57M	$-127.75M	$-110.13M	$-50.26M	$-9.50M	$-61.03M	$-61.47M	$-39.73M	$-54.93M	$-57.54M	$-56.24M	$-29.22M	$-42.50M	$-37.05M	$-40.54M	$-26.17M	$-133.40M	$-101.36M	$-58.85M	$-15.52M	$-8.32M	$-8.62M
Surprise %	-	-	-	-	-	-	-	-	-	0.70%	0.89%	0.91%	5.36%	0.67%	0.46%	0.95%	0.60%	0.46%	0.53%	1.14%	0.56%	0.53%	0.39%	0.75%	0.22%	0.15%	0.24%	0.78%	1.00%	1.00%

Geron's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. GERN's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Geron SG&A Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Jun 18	Mar 17
# Analysts	1	1	1	4	6	3	1	1	3	1	1	1	1	1	1	1	1	1	1	7	5	5	9	6	4	4	7	4	11	7
SG&A	-	-	-	-	-	-	-	-	-	$18.35M	$16.49M	$12.89M	$13.84M	$15.64M	$7.44M	$6.70M	$7.87M	$7.26M	$7.06M	$7.48M	$7.09M	$6.51M	$5.96M	$6.12M	$5.26M	$4.99M	$5.19M	$5.45M	$4.25M	$4.66M
Avg Forecast	$10.17B	$8.72B	$7.37B	$6.08B	$6.60B	$2.02B	$36.76M	$3.07M	$8.69M	$6.29M	$7.04M	$7.46M	$13.27M	$9.22M	$12.12M	$10.81M	$8.17M	$10.76M	$8.81M	$6.61M	$7.40M	$8.14M	$5.88M	$5.66M	$7.74M	$5.29M	$10.61M	$15.09M	$22.21M	$57.11M
High Forecast	$17.96B	$15.41B	$13.02B	$7.51B	$14.72B	$2.07B	$36.77M	$3.08M	$9.31M	$11.11M	$12.43M	$13.18M	$23.44M	$9.22M	$12.12M	$10.81M	$8.17M	$10.76M	$8.81M	$6.61M	$7.40M	$8.14M	$5.88M	$5.66M	$7.74M	$5.29M	$10.61M	$15.09M	$26.65M	$68.53M
Low Forecast	$7.30B	$6.26B	$5.29B	$4.89B	$3.98B	$1.98B	$36.75M	$3.07M	$8.07M	$4.52M	$5.05M	$5.36M	$9.53M	$9.22M	$12.12M	$10.81M	$8.17M	$10.76M	$8.81M	$6.61M	$7.40M	$8.14M	$5.88M	$5.66M	$7.74M	$5.29M	$10.61M	$15.09M	$17.77M	$45.68M
Surprise %	-	-	-	-	-	-	-	-	-	2.92%	2.34%	1.73%	1.04%	1.70%	0.61%	0.62%	0.96%	0.67%	0.80%	1.13%	0.96%	0.80%	1.01%	1.08%	0.68%	0.94%	0.49%	0.36%	0.19%	0.08%

Geron's average Quarter SG&A projection for Dec 23 is $8.69M, based on 3 Wall Street analysts, with a range of $8.07M to $9.31M. The forecast indicates a -52.64% fall compared to GERN last annual SG&A of $18.35M (Sep 23).

Geron EPS Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Jun 18	Mar 17
# Analysts	1	1	1	4	6	3	1	1	3	1	1	1	1	1	1	1	1	1	1	7	5	5	9	6	4	4	7	4	11	7
EPS	-	-	-	-	-	-	-	-	-	$-0.00	$-0.00	$-0.07	$-0.10	$-0.10	$-0.07	$-0.09	$-0.10	$-0.08	$-0.09	$-0.09	$-0.07	$-0.06	$-0.06	$-0.08	$-0.15	$-0.08	$-0.08	$-0.05	$-0.04	$-0.05
Avg Forecast	$-0.01	$-0.02	$-0.03	$-0.04	$-0.03	$-0.08	$-0.10	$-0.10	$-0.08	$-0.10	$-0.08	$-0.10	$-0.12	$-0.09	$-0.09	$-0.10	$-0.08	$-0.09	$-0.09	$-0.08	$-0.07	$-0.06	$-0.06	$-0.12	$-0.20	$-0.15	$-0.09	$-0.07	$-0.04	$-0.05
High Forecast	$-0.01	$-0.01	$-0.02	$-0.01	$0.19	$-0.05	$-0.07	$-0.06	$-0.07	$-0.06	$-0.05	$-0.06	$-0.08	$-0.09	$-0.09	$-0.10	$-0.08	$-0.09	$-0.09	$-0.08	$-0.07	$-0.06	$-0.06	$-0.12	$-0.20	$-0.15	$-0.09	$-0.07	$-0.03	$-0.04
Low Forecast	$-0.02	$-0.04	$-0.06	$-0.06	$-0.19	$-0.17	$-0.21	$-0.19	$-0.09	$-0.19	$-0.17	$-0.20	$-0.25	$-0.09	$-0.09	$-0.10	$-0.08	$-0.09	$-0.09	$-0.08	$-0.07	$-0.06	$-0.06	$-0.12	$-0.20	$-0.15	$-0.09	$-0.07	$-0.05	$-0.06
Surprise %	-	-	-	-	-	-	-	-	-	0.00%	0.00%	0.70%	0.81%	1.07%	0.74%	0.93%	1.19%	0.91%	1.05%	1.15%	1.08%	1.06%	0.97%	0.67%	0.74%	0.52%	0.89%	0.75%	1.00%	1.00%

According to undefined Wall Street analysts, Geron's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to GERN previous annual EPS of $NaN (undefined).

Geron Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
HEPA	Hepion Pharmaceuticals	$0.52	$70.00	13361.54%	Buy
ELEV	Elevation Oncology	$0.67	$9.00	1243.28%	Buy
XFOR	X4 Pharmaceuticals	$0.74	$3.67	395.95%	Buy
PDSB	PDS Bio	$1.96	$9.00	359.18%	Buy
ZURA	Zura Bio	$2.51	$10.00	298.41%	Buy
IMMX	Immix Biopharma	$2.29	$7.00	205.68%	Buy
VKTX	Viking Therapeutics	$46.70	$97.80	109.42%	Buy
GERN	Geron	$3.93	$6.83	73.79%	Buy
SRPT	Sarepta Therapeutics	$125.76	$187.20	48.85%	Buy
MDGL	Madrigal Pharmaceuticals	$306.08	$315.75	3.16%	Buy
PTCT	PTC Therapeutics	$47.02	$48.00	2.08%	Hold
TGTX	TG Therapeutics	$33.57	$23.75	-29.25%	Buy

GERN Forecast FAQ

Is Geron a good buy?

Yes, according to 7 Wall Street analysts, Geron (GERN) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 6 'Buy' recommendations, accounting for 85.71% of GERN's total ratings.

What is GERN's price target?

Geron (GERN) average price target is $6.83 with a range of $5.5 to $8, implying a 90.52% from its last price of $3.58. The data is based on 7 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Geron stock go up soon?

According to Wall Street analysts' prediction for GERN stock, the company can go up by 90.52% (from the last price of $3.58 to the average price target of $6.83), up by 123.15% based on the highest stock price target, and up by 53.42% based on the lowest stock price target.

Can Geron stock reach $5?

GERN's average twelve months analyst stock price target of $6.83 supports the claim that Geron can reach $5 in the near future.

What are Geron's analysts' financial forecasts?

Geron's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $81.28M (high $157.78M, low $56.27M), average EBITDA is $-125M (high $-91.044M, low $-210M), average net income is $-191M (high $9.35M, low $-427M), average SG&A $8.67B (high $16.82B, low $6B), and average EPS is $-0.314 (high $0.00919, low $-0.752). GERN's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $303.41M (high $505.45M, low $222.68M), average EBITDA is $-303M (high $-223M, low $-505M), average net income is $-62.817M (high $-32.116M, low $-117M), average SG&A $32.35B (high $53.89B, low $23.74B), and average EPS is $-0.0949 (high $-0.0485, low $-0.177).

Did the GERN's actual financial results beat the analysts' financial forecasts?

Based on Geron's last annual report (Dec 2022), the company's revenue was $596K, beating the average analysts forecast of $428.52K by 39.08%. Apple's EBITDA was $-135M, beating the average prediction of $-39.348M by 243.14%. The company's net income was $-141M, missing the average estimation of $-164M by -13.75%. Apple's SG&A was $43.63M, missing the average forecast of $45.43M by -3.96%. Lastly, the company's EPS was $-0.37, missing the average prediction of $-0.413 by -10.34%. In terms of the last quarterly report (Sep 2023), Geron's revenue was $164K, beating the average analysts' forecast of $59K by 177.97%. The company's EBITDA was $-47.612M, beating the average prediction of $-59K by 80598.31%. Geron's net income was $-44.805M, missing the average estimation of $-64.009M by -30.00%. The company's SG&A was $18.35M, beating the average forecast of $6.29M by 191.70%. Lastly, the company's EPS was $-0.0001, missing the average prediction of $-0.0967 by -99.90%